Suzhou Sepax Technologies (688758.SH) plans to invest 300 million yuan to build a large-scale protein production and chromatographic packing expansion project.

date
19:17 15/06/2026
avatar
GMT Eight
Sampson Technology (688758.SH) announced that its subsidiary, Yangzhou Sampson, plans to carry out a large-scale protein production and chromatographic filling expansion project in the Bio-Health Industry Park of Yangzhou High-tech Industrial Development Zone. This project aims to establish a large-scale production base for chromatographic filling and protein production. The total investment of this project is estimated to be around 300 million yuan, with a construction period of 24 months.
Suzhou Sepax Technologies (688758.SH) announced that its subsidiary Yangzhou Saifen plans to carry out a large-scale protein production and chromatographic filler expansion project in the Yangzhou High-tech Industrial Development Zone Bio-Health Industry Park. The project aims to build a large-scale production base for chromatographic fillers and protein production. The total investment in this project is approximately 300 million yuan, and the construction period is expected to be 24 months. The subsidiary Yangzhou Saifen of the company intends to purchase land use rights and invest in the construction of a large-scale protein production and chromatographic filler expansion project, as part of the strategic layout and business development needs in the medium to long term. After the implementation of this project, it will comprehensively improve the company's overall chromatographic filler production capacity, expand production capacity, enhance the company's scale production and delivery capabilities, fully meet the continuous growth market demand for chromatographic fillers at home and abroad, and strengthen the foundation of the company's core business development. At the same time, the establishment of a large-scale protein production base will achieve large-scale supply of core raw materials, enabling the company to expand into multiple business tracks such as biologics manufacturing and biopharmaceuticals, enriching the profit model, and continuously enhancing the company's industry-leading advantages.